| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Doxorubicin, (brand name Adriamycin) is a chemotherapy medication used to treat breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. Often used together with other chemotherapy agents. Given by injection into a vein. Doxorubicin is an anthracycline chemotherapy whose core anticancer activity is driven by DNA intercalation and topoisomerase II poisoning (DNA double-strand break stress), with additional contributions from redox cycling/iron-linked oxidative injury in some contexts. Its major clinical limitations are myelosuppression and cumulative dose–dependent cardiomyopathy, plus severe tissue injury if extravasated (leaks outside the vein). -Cumulative cardiomyopathy risk is real and dose-dependent; labels note higher risk at higher cumulative doses (often cited around >550 mg/m², with lower limits in higher-risk patients). -Mechanism split: tumor kill is primarily Topo II + DNA damage, while cardiotoxicity is strongly linked to TOP2β/mitochondrial pathways (redox/iron biology remains discussed, but not the only story). -Administration hazard: extravasation can cause severe local injury;
Time-Scale Flag (TSF): P / R / G
|
| Source: |
| Type: |
| The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”. Possible Chemo-Sensitizers: -Curcumin -Resveratrol -EGCG -Quercetin -Genistein -Berberine -Piperine: alkaloid from black pepper -Ginsenosides: active components of ginseng -Silymarin -Allicin -Lycopene -Ellagic acid -Caffeic acid phenethyl ester -flavopiridol -oleandrin -Ursolic acid -butein -Betulinic acid |
| 4431- | AgNPs, | doxoR, | Oxidative Stress-Induced Silver Nano-Carriers for Chemotherapy |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | 3T3 |
| 1999- | Api, | doxoR, | Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation |
| - | in-vitro, | Nor, | NRK52E | - | in-vitro, | Nor, | MPC5 | - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2586- | Api, | doxoR, | Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway |
| - | in-vitro, | HCC, | Bel-7402 |
| 1363- | Ash, | doxoR, | Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | CaOV3 | - | in-vivo, | NA, | NA |
| 5248- | Ba, | BA, | doxoR, | Baicalin and Baicalein Enhance Cytotoxicity, Proapoptotic Activity, and Genotoxicity of Doxorubicin and Docetaxel in MCF-7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | HUVECs |
| 2591- | CHr, | doxoR, | Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway |
| - | in-vitro, | HCC, | Bel-7402 |
| 6165- | Cin, | doxoR, | Cinnamaldehyde potentiates cytotoxic and apoptogenic effects of doxorubicin in prostate cancer cell line |
| - | in-vitro, | Pca, | PC3 |
| 4763- | CoQ10, | Chemo, | doxoR, | Effect of Coenzyme Q10 on Doxorubicin Cytotoxicity in Breast Cancer Cell Cultures |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 |
| 6532- | CRV, | doxoR, | R-(-)-carvone Attenuated Doxorubicin Induced Cardiotoxicity In Vivo and Potentiated Its Anticancer Toxicity In Vitro |
| - | in-vivo, | BC, | MCF7 | - | in-vivo, | Nor, | H9c2 |
| 6759- | DHA, | doxoR, | Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 1965- | GamB, | doxoR, | Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis |
| - | in-vitro, | Ovarian, | SKOV3 |
| 7680- | iod, | doxoR, | Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection |
| - | vitro+vivo, | BC, | NA |
| 8050- | IVM, | doxoR, | Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma |
| - | in-vitro, | OS, | NA |
| 8190- | LGE, | doxoR, | Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug's Metabolism, Toxicity, and Multidrug Transporters |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Ovarian, | SKOV3 |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF7 |
| 506- | MF, | doxoR, | Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells |
| - | in-vitro, | OS, | LM8 |
| 5610- | NaHCO3, | doxoR, | Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin |
| - | vitro+vivo, | BC, | 4T1 |
| 5216- | PI, | doxoR, | Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 58- | QC, | doxoR, | Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | NA, | CD133+ |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 89- | QC, | doxoR, | Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met |
| - | in-vitro, | Pca, | PC3 |
| 4504- | SeNPs, | Chit, | FA, | doxoR, | pH-responsive selenium nanoparticles stabilized by folate-chitosan delivering doxorubicin for overcoming drug-resistant cancer cells |
| - | in-vitro, | Var, | NA |
| 2129- | TQ, | doxoR, | Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:179 Target#:1106 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid